Unichem Laboratories Q3 FY17 results (Oct–Dec 2016) and concall

Unichem Labs reported strong financial results for Q3 FY17, driven primarily by robust growth in its international formulation business. Despite challenges from demonetization impacting domestic sales, the company maintained positive traction and is strategically expanding its Unienzyme brand into the OTC market. Management highlighted ongoing R&D investments and a healthy pipeline of ANDA filings, while acknowledging potential short-term disruptions from GST implementation and persistent US generics price erosion.